UK markets open in 2 hours 19 minutes

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
761.30+30.40 (+4.16%)
At close: 04:59PM CEST
Full screen
Previous close730.90
Open734.60
Bid761.30 x 0
Ask761.30 x 0
Day's range732.00 - 762.50
52-week range475.45 - 834.50
Volume1,891,591
Avg. volume2,082,922
Market cap1.726T
Beta (5Y monthly)0.25
PE ratio (TTM)35.41
EPS (TTM)21.50
Earnings dateN/A
Forward dividend & yield10.40 (1.37%)
Ex-dividend date25 Mar 2022
1y target est784.25
  • Zacks

    Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo

    Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.

  • Zacks

    4 Large Drug Stocks to Watch as the Industry Recovers

    Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.

  • Globe Newswire

    Novo Nordisk A/S: Share repurchase programme

    Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate